Afatinib-850140-72-6

Irreversible ErbB series blockers.

Afatinib not only acts against EGFR mutations targeted by first-generation tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib, but also has resistance to these drugs Less common mutations.